Mark S. Shaefer

High Sensitivity of Human Leukocyte Antigen–B*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients

Michael S. Saag, Rukmini Balu, Elizabeth J. Phillips et al. · Clinical Infectious Diseases · 2008 · 429 citations · Full text

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Edgar T. Overton, Gary Richmond, Giuliano Rizzardini et al. · The Lancet · 2020 · 342 citations

Phase 3B, Treatment And Prevention, Clinical Epidemiology +10

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

Joseph J. Eron, Patrick Yéni, Joseph Gathe et al. · The Lancet · 2006 · 341 citations

Klean Study, Treatment And Prevention, Hiv Infection +9

Pharmacokinetics of tacrolimus in liver transplant patients*

William J. Jusko, Wojciech Piekoszewski, Göran B. Klintmalm et al. · Clinical Pharmacology & Therapeutics · 1995 · 238 citations

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

Kimberly Y. Smith, Parul Patel, Derek M. Fine et al. · AIDS · 2009 · 217 citations